Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2017
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 28 Jun 2017 Planned End Date changed from 1 Apr 2023 to 27 Jul 2021.
- 28 Jun 2017 Planned primary completion date changed from 1 Apr 2023 to 27 Jul 2021.
- 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.